ARTICLE | Company News
Sanofi suit: Merck's follow-on biologic infringes Lantus patents
September 19, 2016 7:00 AM UTC
In a suit filed in federal court, Sanofi (Euronext:SAN; NYSE:SNY) alleged Merck & Co. Inc. (NYSE:MRK) infringed 10 of its patents covering the pharma's Lantus insulin glargine and Lantus SoloStar pen.
Last month, Merck said FDA accepted for filing an NDA for MK-1293 to treat Type I and Type II diabetes. The candidate is a follow-on biologic of Lantus, a synthetic sustained-release subcutaneous insulin analog. ...